The procedure includes mobilization of CD34+ HSPCs from the bone marrow to circulation after treatment with pharmaceutical reagents such as the granulocyte-colony stimulating factor G-CSF in combination with Plerixafor (AMD3100; MozobilTM) in thalassemia patients [9,10,11], or Plerixafor alone in SCD patients [12]. The gene discussed is CSF3; the disease is Schnyder corneal dystrophy.